AbCellera Biologics (ABCL) said late Thursday it will present phase 1/2 data on ABCL635, its investigational antibody treatment for menopause-related hot flashes, at The Menopause Society's 2026 annual meeting in San Diego.

The presentation will include safety, pharmacokinetic, pharmacodynamic and efficacy data, including new safety results from the phase 1 multiple ascending dose study and new patient-reported outcomes from the phase 2 trial.

ABCL635 is being evaluated as a non-hormonal, long-acting treatment for moderate-to-severe vasomotor symptoms associated with menopause, the biotechnology company said.

Shares of AbCellera Biologics were up more than 4% in Friday trading.

Price: 12.60, Change: +0.58, Percent Change: +4.83